Corbus Pharmaceutica (CRBP) 3.25 $CRBP Corbus

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 9:16 PM

Corbus Pharmaceutica (CRBP) 3.25 $CRBP

Corbus Pharmaceuticals Receives $5 Million Development Award From Cystic Fibrosis Foundation Therapeutics to Advance Resunab(TM) Clinical Program
Marketwired - Wed Apr 22, 6:05AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (the "Company"

, a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that it has received a development award for up to $5 million from Cystic Fibrosis Foundation Therapeutics, Inc. ("CFFT"

, the non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation. The development award will help support a first-in-patient Phase 2 clinical trial of the Company's oral anti-inflammatory drug Resunab(TM) in adults with cystic fibrosis ("CF"

.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Apr 16, 9:00AM CDT
What:
CRBP: 3.25 (+0.48), NDAQ: 48.84 (+0.12)

OTC Markets Group Congratulates Corbus Pharmaceuticals Holdings on Uplisting to NASDAQ from OTCQB Venture Marketplace
PR Newswire - Thu Apr 16, 8:25AM CDT
OTC Markets Group Inc. (OTCQX: OTCM) congratulates Corbus Pharmaceuticals Holdings, Inc., a clinical stage biopharmaceutical company, on its uplisting to the NASDAQ Capital Market. Corbus previously traded on OTCQB®, America's venture market for entrepreneurial and development stage companies.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals Announces Initiation of Trading on The Nasdaq Capital Market
Marketwired - Thu Apr 16, 6:35AM CDT
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company focused on the development and commercialization of treatments for rare, life-threatening inflammatory and fibrotic diseases, announced that its common stock will begin trading today on The Nasdaq Capital Market (NASDAQ) under the current ticker symbol, CRBP.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals Announces Uplisting to The NASDAQ Capital Market
Marketwired - Mon Apr 13, 2:09PM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab,(TM) for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that the NASDAQ Stock Market LLC has approved the Company's application to have its common stock listed on The NASDAQ Capital Market (NASDAQ). The stock will commence trading on The NASDAQ Capital Market on April 16, 2015, under its existing ticker symbol CRBP.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals Announces Presentation of Positive Data on Anti-Fibrotic Effects of Resunab(TM) in a Preclinical Model of Lung Fibrosis at the Experimental Biology 2015 Scientific Conference
Marketwired - Wed Apr 01, 7:00AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), a clinical stage drug development company focused on the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that positive pre-clinical data on the anti-fibrotic effects of Resunab(TM) will be presented today at the Experimental Biology 2015 scientific conference.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals' IND Receives Clearance From FDA to Initiate Phase 2 Trials in Scleroderma With Its Novel Specialized Pro-Resolving Mediator Drug Resunab(TM)
Marketwired - Mon Mar 09, 7:35AM CDT
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the Company), announced today that company's Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) is now open and it is authorized to initiate a Phase 2 clinical study with Resunab(TM) for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).
CRBP: 3.25 (+0.48)

Corbus Plans Multiple Clinical Trials With Resunab In Orphan Indications
Jason Napodano, CFA - at Seeking Alpha - Wed Feb 11, 2:10PM CST

CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals to Present at the Leerink Global Healthcare Conference on February 11, 2015
Marketwired - Wed Feb 11, 6:35AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"

, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2014.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals to Present at the 17th Annual BIO CEO & Investor Conference on February 9, 2015
Marketwired - Mon Feb 02, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"

, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that its Chief Executive Officer, Yuval Cohen, Ph.D., will be presenting at two upcoming investor conferences in January, 2015.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals to Present at the Oppenheimer 25th Annual Healthcare Conference on December 10, 2014
Marketwired - Wed Dec 03, 7:05AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"

, an emerging drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today it will be presenting at the Oppenheimer & Co. 25th Annual HealthCare Conference being held December 10-11, 2014, at the Crowne Plaza Hotel in New York, New York.
CRBP: 3.25 (+0.48)

Eight Companies Webcast Live to Investors, December 4th at VirtualInvestorConferences.com
CNW Group - Tue Dec 02, 7:29AM CST
CEOs and top executives to take questions in real-time during formal roadshow presentations as well as meet and "chat" in virtual trade booths
SMLR: 3.25 (+0.08), CRBP: 3.25 (+0.48), ONVO: 5.14 (+0.67), CYTX: 0.96 (-0.09), IAG: 2.10 (-0.09)

Corbus Pharmaceuticals to Present at VirtualInvestorConferences.com Online Event on December 4, 2014
PR Newswire - Mon Dec 01, 8:42AM CST
Corbus Pharmaceuticals Holdings, Inc. (OTCQB: CRBP) (the "Company"

, an emerging growth drug development company focused on the development and commercialization of its lead product candidate, Resunab(TM), for the treatment of rare, life-threatening inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will be presenting at VirtualInvestorConferences.com, a live and interactive online event, on Thursday, December 4, 2014 at 11:30 a.m. Eastern Standard Time.
CRBP: 3.25 (+0.48)

Fort Point Angels Scores First Successful "Exit"
PR Newswire - Mon Dec 01, 8:37AM CST
Fort Point Angels LLC, an angel investment fund that makes seed and early-stage investments in growth-industry companies, announced its first successful "exit" with the initial public offering of Corbus Pharmaceuticals Holdings Inc., of Norwood, MA.
CRBP: 3.25 (+0.48)

Corbus Pharmaceuticals reports Q3 earnings
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:18AM CST

CRBP: 3.25 (+0.48)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Drowsy Driving Forum Spurs United Call for Safety Action

A Fresh Coalition Against a Familiar Foe On a brisk late October day, the National Sleep Foundation (NSF) pulled together a motley crew of road safety veterans, vehicle makers, crash sniffers, and sleep legends at the National Press Club. This wasn't just another talkfest. With an estimated 61% of U.S. adults reportedly driving while half-asleep, something finally shook...

tZERO Gains CFTC Approval, Paves Derivatives Path

Breaking into New Territory: tZERO's CFTC Triumph tZERO just scored a touchdown in the financial arena with its newly minted approval from the Commodity Futures Trading Commission. This green light allows them to dive into derivatives trading and clearing, a colossal leap for their Infrastructure-as-a-Service model. You could almost feel the corporate chest-thumping as...

Class Action Looms Over The Chemours Company

Chemours Under Fire: What’s Happening? Here we are, in the thick of a legal storm surrounding The Chemours Company. A class-action lawsuit is underway, and it’s painting the company in a rather unflattering light. Now, if you snagged some of that NYSE:CC action between February 20, 2026, and August 4, 2026, there's a chance you’re caught in the crossfire. Per the...

Global Case Studies in Poverty Reduction Spotlighted

A Fresh Spotlight on Poverty Reduction Efforts Amid the clamor of social and economic challenges, 126 stellar case studies of poverty reduction just took center stage at a seminar in Beijing. These admired initiatives emerged from the seventh global solicitation, chosen from a pile of 890 entries submitted by do-gooders and organizations spanning 31 countries. If you've...

LA Auto Show Partners with PetSet: A Charitable Drive

A Unique Partnership Between Cars and Compassion Los Angeles is no stranger to the vibrant blend of culture and cars. This year, the Los Angeles Auto Show decided to steer things to a new lane of compassion by teaming up with PetSet. Now, if you're scratching your head wondering how the automobile world rides in tandem with animal welfare, grab a seat. The 'Road to Home...

Data Centers: More Power-Hungry Than Thirsty

Data Centers: Not Quite the Water Guzzlers We Feared Hold onto your hats, because the latest intel on data centers is changing the game, or at least forcing a closer look at what seems like a done deal. The big reveal? It's not the water, folks—it’s the juice. While everyone frets about water, electricity is the silent giant you’ve got to wrangle. Water vs....

Regal Intel Pursues Uncharted Territory in Rare Disease Research

New insights don't just appear out of thin air, and in the world of rare diseases, they’re often stuck behind data that’s never quite been tackled the right way. Here comes Regal Intel, a nonprofit making waves by diving into the deep end with two fresh seed grants. These folks are hell-bent on making sense of skin-deep and gut-wrenching issues that science hasn't...

Animal Rescue Corps Executes Operation Cage Breaker

ARC Springs Into Action in Rural Florida You ever think about those days where you feel like you're running against the current? That sums up the recent ordeal in Branford, Florida, where Animal Rescue Corps (ARC), a nonprofit, rolled up their sleeves for a major task under Operation Cage Breaker. This wasn’t some run-of-the-mill animal shelter duty. We’re talking a...

Wyalusing Valley, Wysox Centers Change Ownership

A New Chapter for Pennsylvania's Childcare Gems In the often unpredictable world of childcare services, a shift is happening in Pennsylvania that has John and Robyn Lacy stepping back after two decades of dedicated service. The Wyalusing Valley Children's Center and Wysox Children's Center have found a new home in the hands of a private investor, signifying a significant...

HelloNation Spotlights Michigan Manufacturers' Achievements

A Night of Recognition and Innovation Awaits Alright, folks, here's a story brewed from Michigan's manufacturing heartland. As the state gears up for the annual 2026 Manufacturing Excellence Awards, there's more being served up in Plymouth than just a fancy dinner and applause. CGI Digital and their posse at HelloNation are stepping into the fray, not just to clap...